Oral Dose Escalation of Tac-101 in Advanced Malignancies

$0M01FY2000RRNIH

Georgetown University, Washington DC

Investigators

Linked publications & trials

Paper 32333300 Paper 23450847 Paper 23240883 Paper 23063445 Paper 22615713 Paper 22461299 Paper 22363411 Paper 22174377 Paper 21698649 Paper 21592494 Paper 21484949 Paper 21390918 Paper 20585350 Paper 20431969 Paper 20425007 Paper 20123264 Paper 20036166 Paper 19998356 Paper 19941845 Paper 19698724 Paper 19595914 Paper 19421167 Paper 19384887 Paper 19293567 Paper 19076391 Paper 19076386 Paper 19068486 Paper 19018086 Paper 18657684 Paper 18417057 Paper 18358240 Paper 18241673 Paper 18025875 Paper 17936741 Paper 17898655 Paper 17852720 Paper 17534049 Paper 17465859 Paper 17437680 Paper 17364143 Paper 17283739 Paper 17188675 Paper 17157339 Paper 17153033 Paper 17145202 Paper 17012292 Paper 16936702 Paper 16786505 Paper 16707118 Paper 16546424 Paper 16527354 Paper 16490008 Paper 16489081 Paper 16441255 Paper 16439609 Paper 16418685 Paper 16395185 Paper 16364180 Paper 16321154 Paper 16313930 Paper 16258904 Paper 16242123 Paper 16171832 Paper 16169406 Paper 16032641 Paper 16018881 Paper 16018880 Paper 15996010 Paper 15934062 Paper 15910515 Paper 15880832 Paper 15827573 Paper 15795649 Paper 15737784 Paper 15730597 Paper 15714518 Paper 15650363 Paper 15607706 Paper 15606911 Paper 15588296 Paper 15530188 Paper 15529297 Paper 15504323 Paper 15480384 Paper 15478168 Paper 15477496 Paper 15469872 Paper 15345350 Paper 15340113 Paper 15313142 Paper 15266197 Paper 15228148 Paper 15157559 Paper 15133310 Paper 15121987 Paper 15115693 Paper 15050975 Paper 15050968 Paper 15043485 Paper 15041713

Abstract

The primary objectives of this study are to determine the maximum tolerated dose for TAC-101 in patients with malignancies unresponsive to standard therapy or for which there is no standard treatment, and to evaluate the safety of chronic daily adminisstration of TAC-101. Secondary objectives are to study the pharmacokinetics of TAC-101 in patients with cancer, and to detect any evidence of antitumor activity of TAC-101. This escalating study will enroll three subjects per dose level, with 6 subjects at the maximum tolerated dose.

View original record on NIH RePORTER →